Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Clinical trial NCT05583149 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05583149
Sponsor: Patrick C. Johnson, MD
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Refractory Aggressive B-cell Lymphomas Refractory B-Cell Non-Hodgkin Lymphoma Aggressive B-cell NHL Diffuse Large B-cell Lymphoma (DLBCL)De Novo or Transformed Indolent B-cell Lymphoma DLBCL, Nos Genetic Subtypes T Cell/Histiocyte-rich Large B-cell Lymphoma EBV-Positive DLBCL, Nos Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)High-Grade B-Cell Lymphoma, Nos C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma Grade 3b Follicular Lymphoma

Start date: 2023-03-01
Primary completion: 2024-11-23
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.